Journal
JOURNAL OF CELL BIOLOGY
Volume 197, Issue 7, Pages 997-1008Publisher
ROCKEFELLER UNIV PRESS
DOI: 10.1083/jcb.201109091
Keywords
-
Categories
Funding
- National Health and Medical Research Council (NHMRC
- Australia) [526648, 1006488]
- Muscular Dystrophy Association (USA) [69684]
- National Institutes of Health [AG033610]
- NHMRC [1013533, 586604]
- Australian Research Council [FT0001657]
- Pfizer Australia
- Victorian Government
Ask authors/readers for more resources
Follistatin is essential for skeletal muscle development and growth, but the intracellular signaling networks that regulate follistatin-mediated effects are not well defined. We show here that the administration of an adeno-associated viral vector expressing follistatin-288aa (rAAV6:Fst-288) markedly increased muscle mass and force-producing capacity concomitant with increased protein synthesis and mammalian target of rapamycin (mTOR) activation. These effects were attenuated by inhibition of mTOR or deletion of S6K1/2. Furthermore, we identify Smad3 as the critical intracellular link that mediates the effects of follistatin on mTOR signaling. Expression of constitutively active Smad3 not only markedly prevented skeletal muscle growth induced by follistatin but also potently suppressed follistatin-induced Akt/mTOR/S6K signaling. Importantly, the regulation of Smad3- and mTOR-dependent events by follistatin occurred independently of overexpression or knockout of myostatin, a key repressor of muscle development that can regulate Smad3 and mTOR signaling and that is itself inhibited by follistatin. These findings identify a critical role of Smad3/Akt/mTOR/S6K/S6RP signaling in follistatin-mediated muscle growth that operates independently of myostatin-driven mechanisms.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available